Fox Run Management, L.L.C. Adverum Biotechnologies, Inc. Transaction History

Fox Run Management, L.L.C.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Oct 05, 2018	SELL	$4.5 - $7.6 $67,950 - $114,760	-15,100 Closed	0 $0
Q2 2018 Jul 17, 2018	BUY	$5.3 - $6.9 $22,175 - $28,869	4,184 Added 38.33%	15,100 $80,000
Q1 2018 Apr 17, 2018	BUY	$3.65 - $7.95 $39,843 - $86,782	10,916 New	10,916 $63,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $520M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.